THE CANCER GENOME ATLAS Research Network, including more than 300 researchers from 44 institutions, found that molecular diagnostics are much more precise and reproducible than looking at tissue under a microscope for classification of diffuse gliomas.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
